Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)  - Pipeline Review, H2 2016', provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)  targeted pipeline therapeutics. 

The report provides comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)  targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) 
- The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)  targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)  targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)  targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)  targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)  development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Overview 9
Therapeutics Development 10
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Stage of Development 10
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Therapy Area 11
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Indication 12
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Companies 17
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Universities/Institutes 21
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development 30
Aduro BioTech, Inc. 30
Agenus, Inc. 31
Alligator Bioscience AB 32
AlphaMab Co., Ltd 33
Bristol-Myers Squibb Company 34
Cold Genesys, Inc. 35
CytomX Therapeutics, Inc. 36
Immunocore Limited 37
JHL Biotech, Inc. 38
Lytix Biopharma AS 39
MedImmune, LLC 40
Novartis AG 41
OncoImmune, Inc. 42
Premier Biomedical Inc 43
PsiOxus Therapeutics Limited 44
Sutro Biopharma, Inc. 45
Theravectys SA 46
Tikcro Technologies, Ltd. 47
Xencor, Inc. 48
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles 49
AGEN-1884 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
AGEN-2041 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Antisense Oligonucleotide to Inhibit CTLA4 for Oncology - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ATOR-1015 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Biologic to Antagonize CTLA4 for Solid Tumor - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
CG-0070IT - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
CG-0161 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
durvalumab + IMCgp-100 + tremelimumab - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
durvalumab + tremelimumab - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ipilimumab - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
JMW-3B3 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
KN-044 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
LTX-315 + Anti-CTLA4 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
MEDI-0562 + tremelimumab - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
MEDI-3617 + tremelimumab - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Monoclonal Antibodies to Inhibit CTLA-4 for Metastatic Melanoma - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Monoclonal Antibody to Antagonize CTLA-4 for Oncology - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Monoclonal Antibody to Inhibit CTLA4 for Oncology - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
ONC-392 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Oncolytic Viruses to Antagonize CTLA4 for Solid Tumors - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
SNCA-21 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
tremelimumab - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
XmAb-20717 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Projects 93
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products 95
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Featured News & Press Releases 96
Oct 08, 2016: Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study 96
Sep 06, 2016: Mesothelioma Treatment Center at Baylor St. Luke's launches clinical trial of cancer combination therapy 97
Jul 27, 2016: Combining Ipilimumab with local treatments improved survival for patients with melanoma 98
Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients 99
Apr 27, 2016: Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors 100
Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN2041 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 101
Feb 29, 2016: AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma 102
Feb 17, 2016: Immune-targeting drug combo shows promise for lung cancer patients, says Moffitt 102
Feb 08, 2016: Astrazeneca'S Combination of Durvalumab with Tremelimumab Shows Clinical Activity in Non-Small Cell Lung Cancer Irrespective Of PD-L1 Status 103
Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-CTLA-4 Antibody 104
Oct 28, 2015: Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma 105
Oct 19, 2015: Cold Genesys Announces FDA Acceptance of a Phase I/II Clinical Trial Using CG0070 Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer 106
Jun 02, 2015: AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015 107
May 31, 2015: Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo + Yervoy Regimen or Opdivo Monotherapy vs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Melanoma 108
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112

List of Tables

Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Comparative Analysis by Unknown Stage Development, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Pipeline by Aduro BioTech, Inc., H2 2016 30
Pipeline by Agenus, Inc., H2 2016 31
Pipeline by Alligator Bioscience AB, H2 2016 32
Pipeline by AlphaMab Co., Ltd, H2 2016 33
Pipeline by Bristol-Myers Squibb Company, H2 2016 34
Pipeline by Cold Genesys, Inc., H2 2016 35
Pipeline by CytomX Therapeutics, Inc., H2 2016 36
Pipeline by Immunocore Limited, H2 2016 37
Pipeline by JHL Biotech, Inc., H2 2016 38
Pipeline by Lytix Biopharma AS, H2 2016 39
Pipeline by MedImmune, LLC, H2 2016 40
Pipeline by Novartis AG, H2 2016 41
Pipeline by OncoImmune, Inc., H2 2016 42
Pipeline by Premier Biomedical Inc, H2 2016 43
Pipeline by PsiOxus Therapeutics Limited, H2 2016 44
Pipeline by Sutro Biopharma, Inc., H2 2016 45
Pipeline by Theravectys SA, H2 2016 46
Pipeline by Tikcro Technologies, Ltd., H2 2016 47
Pipeline by Xencor, Inc., H2 2016 48
Dormant Projects, H2 2016 93
Dormant Projects (Contd..1), H2 2016 94
Discontinued Products, H2 2016 95